Shares of Aurora Cannabis (ACB) - Get Report dropped Friday after the company's fiscal third quarter came up short of Wall Street's expectations, prompting a number of analysts to cut their ratings and price targets.
For the third quarter ended March 31, the Calgary, Alberta, cannabis company reported a loss of C$165.7 million ($US136.6 million), or a loss of C$0.85 a share, on revenue of C$55.2 million. Analysts surveyed by FactSet were expecting a loss of C$0.25 a share on revenue of C$68.7 million.
"Consistent with many of our peers, the quarter presented challenges in the Canadian adult-use segment. This reinforces the importance of Aurora's broadly diversified business model that balances domestic medical, international medical, and adult-use platforms," Chief Executive Miguel Martin said in a statement.
Analysts at ATB downgraded the stock to underperform from sector perform while cutting the price target to C$7.50 from C$13, saying the company's near-term growth outlook remains uncertain.
FedEx Falls After Earnings as Cost Pressures Accelerate
FedEx falls after reporting quarterly results that beat forecasts but saying cost pressures including labor and fuel costs could weigh on future earnings.
Canaccord Genuity analyst Matt Bottomley downgraded the stock to sell from hold while halving his price target to C$7.
Desjardin analyst John Chu maintained a sell rating while lowering the price target to C$8 from C$11. The third-quarter report included some of the concerns Chu has had since his February downgrade of the stock to sell. Those concerns included a loss of recreational-market and growth uncertainty.
Cantor Fitzgerald remained neutral while lowering its price target to C$9 from C$11.25. The investment firm called out the company's 21% revenue miss and large inventory impairment.
Aurora Cannabis shares at last check were down 9.2% to $6.65.